Short answer
Azenta, Inc. (AZTA) filed its fiscal 2026 10-K annual report with the SEC on Nov 19, 2026. It reported revenue of $622M (+4.7% year over year) and net income of −$167M.
- Top risk flagged: BIOSECURE Act restrictions, including BGI- or MGI-related platforms, could constrain China-based genomic services and supplier access
FY2026 key financial metrics · XBRL
- Revenue
- $622M
- +4.7% YoY
- Net income
- −$167M
- −199.5% YoY
- Operating margin
- -28.1%
- −23.6 pp YoY
- Gross margin
- 44.2%
- −1.3 pp YoY
- EPS (diluted)
- −$3.70
- −203.3% YoY
- ROE
- -12.0%
- −8.7 pp YoY
- Operating cash flow
- $58M
- −20.3% YoY
Source: XBRL data from the Azenta, Inc. (AZTA) FY2026 10-K on SEC EDGAR. USD.
Azenta, Inc. FY2026 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core model: Life sciences sample management and multiomics solutions spanning storage, genomics, consumables, informatics and repository services
- New emphasis: SynPlexity acquisition and Elegen license expanding multiplexed gene libraries and cell-free DNA synthesis
- Strategic shift: B Medical Systems divestiture for $63.0 million, sharpening focus on Sample Management Solutions and Multiomics
- Restructuring: Three North American Multiomics laboratories slated for closure, targeting approximately $11.0 million annualized savings
- Scale: Approximately 2,850 workers, 11,000 customers, sales in approximately 87 countries and 12 genomic laboratories globally
Management Discussion & Analysis
- Revenue $621.7M, up 4.7% YoY from $593.8M, driven by SMS and Multiomics growth
- Gross margin 44.2% vs 45.5%; operating loss $174.7M vs $26.8M, including $149.1M goodwill impairment
- Best segment SMS: revenue $344.4M, adjusted operating income $25.2M; worst Multiomics: adjusted operating loss $15.4M
- Operating cash flow $57.5M; capex $30.1M; share repurchases $118.3M; no dividends planned
- Fiscal 2027 risks: declining Sanger revenue, constrained capital spending, tariffs, lower interest income, and $11.0M to $13.0M restructuring charges
Risk Factors
- BIOSECURE Act restrictions, including BGI- or MGI-related platforms, could constrain China-based genomic services and supplier access
- China exposure: $74.4 million revenue and $177.4 million foreign-currency cash in fiscal 2026
- Sole- or limited-source suppliers for cryogenic systems, consumables and genomic services create disruption risk
- AI-enabled discovery and autonomous laboratories could reduce physical testing demand and intensify competition
- CEO resignation on August 22, 2026, leaves a director as Interim CEO during permanent successor search
Generated from the filing text; verify against the original. How to read a 10-K
Other Azenta, Inc. annual reports
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.